levetiracetam injection, solution, concentrate
mylan institutional llc - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam 100 mg in 1 ml - levetiracetam injection is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. levetiracetam injection is indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. levetiracetam injection is indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy. levetiracetam injection is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible. levetiracetam injection is contraindicated in patients with a hypersensitivity to levetiracetam. reactions have included anaphylaxis and angioedema [see warnings and precautions (5.3)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), including levetiracetam, during pregnancy. encourage women who are
bretylium tosylate injection
ani pharmaceuticals, inc. - bretylium tosylate (unii: 78zp3yr353) (bretylium - unii:rzr75eq2kj) - bretylium tosylate injection, usp is indicated in the prophylaxis and therapy of ventricular fibrillation. bretylium tosylate injection, usp is also indicated in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine. use of bretylium tosylate injection, usp should be limited to intensive care units, coronary care units or other facilities where equipment and personnel for constant monitoring of cardiac arrhythmias and blood pressure are available. following injection of bretylium tosylate there may be a delay of 20 minutes to 2 hours in the onset of antiarrhythmic action, although it appears to act within minutes in ventricular fibrillation. the delay in effect appears to be longer after intramuscular than after intravenous injection. there are no contraindications to use in treatment of ventricular fibrillation or life-threatening refractory ventricular arrhythmias, excep
levetiracetam injection, solution, concentrate
hainan poly pharm. co., ltd. - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 1 month of age and older with epilepsy. levetiracetam injection is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible. levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. levetiracetam injection is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible. levetiracetam is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. levetiracetam injection is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible. levetiracetam is contraindicated in patients with a hypersensitivity to levetiracetam
levetiracetam injection
solco healthcare us, llc - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam injection is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. levetiracetam injection is indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. levetiracetam injection is indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy. levetiracetam injection is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible. levetiracetam injection is contraindicated in patients with a hypersensitivity to levetiracetam. reactions have included anaphylaxis and angioedema [see warnings and precautions ( 5.3)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), including levetiracetam, during pregnancy. encourage women who a
disipal 50mg tablets
astellas pharma ltd - orphenadrine hydrochloride - oral tablet - 50mg
disipal 50mg tablets
de pharmaceuticals - orphenadrine hydrochloride - oral tablet - 50mg
disipal 50mg tablets
stephar (u.k.) ltd - orphenadrine hydrochloride - oral tablet - 50mg
disipal 50mg tablets
mawdsley-brooks & company ltd - orphenadrine hydrochloride - oral tablet - 50mg
disipal 50mg tablets
sigma pharmaceuticals plc - orphenadrine hydrochloride - oral tablet - 50mg
disipal 50mg tablets
waymade healthcare plc - orphenadrine hydrochloride - oral tablet - 50mg